Home・Listă Acțiuni・Arvinas Inc

Arvinas Inc

Închisă

SectorSănătate

8.94 11.75

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

Maxim

9.61

Indicatori cheie
By Trading Economics
Venit	9.8M -58M
Vânzări	6.1M 16M
EPS	-0.9
Marjă de profit	-369.231
Angajați	246
EBITDA	9.6M -56M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+80.77% upside

Dividende
By Acuity
Următoarele câștiguri	4 nov. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-103M 520M
Deschiderea anterioară	-2.81
Închiderea anterioară	8.94

Sentimentul știrilor

By Acuity

43%

57%

160 / 340 Clasament în Healthcare

Arvinas Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 aug. 2026, 20:02 UTC

Social Media

News

Arvinas Inc shares rose following strong Q2 results, with EPS of $2.58 and revenue of $249.7 million, surpassing analyst expectations. BTIG reiterated its Buy rating.

3 aug. 2026, 19:46 UTC

News

Arvinas Inc. shares are lower today, continuing a downward trend since Friday. Barclays raised its price target from $18.00 to $20.00 while maintaining an "overweight" rating.

31 iul. 2026, 20:06 UTC

Arvinas Inc shares are declining amid broader market trends and rising Treasury yields. The stock remains below its 20-day moving average.

29 iul. 2026, 16:36 UTC

Arvinas shares are lower today, trading near the lower end of their one-month range amid rising oil prices and inflation concerns.

28 iul. 2026, 20:06 UTC

Arvinas Inc's shares are lower today, reflecting broader market trends amid a significant decline in Asian indices, particularly the Nikkei 225.

24 iul. 2026, 19:26 UTC

Arvinas Inc. shares are lower amid a broader market decline influenced by falling crude oil prices, now near the lower end of their one-month range.

22 iul. 2026, 20:06 UTC

Arvinas Inc. shares are near unchanged amid routine trading and cautious market sentiment ahead of the Federal Reserve meeting.

21 iul. 2026, 20:06 UTC

Arvinas Inc shares are higher during Tuesday's session, tracking gains in the Nasdaq 100 Index amid strong technology sector performance. No specific news was identified.

Comparație

Modificare preț

Arvinas Inc Așteptări

Obiectiv de preț

By TipRanks

80.77% sus

Prognoză pe 12 luni

Medie 14.57 USD 80.77%

Maxim 20 USD

Minim 6 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArvinas Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

9 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 9 analiști care au acordat evaluări ale acțiunilor Arvinas Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

160 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.